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Abstract
Prebiotic oligosaccharides have the ability to generate important changes in the gut microbiota composition that may confer health beneﬁts to
the host. Reducing the impurities in prebiotic mixtures could expand their applications in food industries and improve their selectivity and
prebiotic effect on the potential beneﬁcial bacteria such as biﬁdobacteria and lactobacilli. This study aimed to determine the in vitro potential
fermentation properties of a 65% galacto-oligosaccharide (GOS) content Bimuno® GOS (B-GOS) on gut microbiota composition and their
metabolites. Fermentation of 65% B-GOS was compared with 52% B-GOS in pH- and volume-controlled dose–response anaerobic batch
culture experiments. In total, three different doses (1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 0·033 g/l) were tested. Changes in the gut
microbiota during a time course were identiﬁed by ﬂuorescence in situ hybridisation, whereas small molecular weight metabolomics proﬁles
and SCFA were determined by 1H-NMR analysis and GC, respectively. The 65% B-GOS showed positive modulation of the microbiota
composition during the ﬁrst 8 h of fermentation with all doses. Administration of the speciﬁc doses of B-GOS induced a signiﬁcant increase in
acetate as the major SCFA synthesised compared with propionate and butyrate concentrations, but there were no signiﬁcant differences
between substrates. The 65% B-GOS in syrup format seems to have, in all the analysis, an efﬁcient prebiotic effect. However, the applicability
of such changes remains to be shown in an in vivo trial.
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SCFA
In vitro and in vivo studies involving prebiotic oligosaccharides
have been carried out using inulin and its fructo-
oligosaccharide (FOS) derivatives, as well as various galacto-
oligosaccharides (GOS). It has been shown that these food
ingredients have the ability to improve selectively the growth of
biﬁdobacteria, and consequently lead to important changes in
the gut microbiota composition that may confer health beneﬁts
to the host. To date, GOS has been associated with numerous
health beneﬁts such as low energy content, insulin-independent
metabolism and stimulation of growth and metabolism of spe-
ciﬁc colonic microbiota. The two main mechanisms by which
this is achieved are through the production of SCFA from its
fermentation and the selective enhancement of beneﬁcial gut
organisms(1). GOS can be deﬁned as a mixture of the end
products of lactose breakdown by β-galactosidases, containing
two to eight saccharide units, with a terminal glucose unit(2).
These mixtures can be complex and their structures are often
imperfectly characterised. They tend to be mixtures of β-1,3,
β-1,4 and β-1,6 linkages with degrees of polymerisation ranging
from two to ﬁve. A characteristic of GOS is that the set of
structures present depends on the source of the enzyme used to
bring about synthesis. The structural and functional relationship
of GOS plays a role in targeting the Biﬁdobacterium genus(3).
Another important aspect is the presence of impurities such as
monosaccharaides, disaccharides or metabolic products from
puriﬁcation steps. Removing these compounds can lead to a
mixture with a GOS content as high as possible that can be
better used to study fermentation and structural properties of
novel prebiotics in in vitro experiments. In addition, puriﬁed
Bimuno® GOS (B-GOS) mixture might have signiﬁcantly
increased interest in production and application in various food
and pharmaceutical processes, especially if the prebiotic is
incorporated directly into food such as diabetic or low-energy
foods. Reducing monosaccharides and disaccharides such as
Abbreviations: B-GOS, Bimuno® galacto-oligosaccharide; GOS, galacto-oligosaccharide.
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glucose, galactose and lactose from the mixture might help
minimise their impact on consumers, particularly by taking into
account lactose intolerance. Several techniques have been
suggested in order to obtain high recovery of GOS, but all of
them have some limitations(4). B-GOS (Bimuno® 52% GOS
content; Clasado Biosciences Ltd) refers to prebiotic GOS
compounds that have multiple biological health activities within
the colonic environment. It is produced from the activity of
galactosidase enzymes isolated from Biﬁdobacterium biﬁdum
NCIMB 41171(5). The method for B-GOS puriﬁcation has been
studied by Goulas et al.(6) in order to reduce the amount of free
glucose and galactose produced during its synthesis, and it led
to the removal of 92% of glucose by fermentation with
Saccharomyces cerevisiae. The biﬁdogenic properties of B-GOS
have been investigated in vitro and in vivo. Tzortzis et al.(7)
showed in vitro and in a pig trial the prebiotic potential of GOS.
In this study, it was established that B-GOS prebiotic activity
was relevant in terms of increase in biﬁdobacteria numbers,
SCFA production and decreased pH, compared with other
prebiotics such as inulin and other GOS types(7). B-GOS has
also been tested in healthy volunteers, clinical conditions that
have a purported microbial aetiology such as irritable bowel
syndrome, traveller’s diarrhoea and obesity, and on cognitive
functions(8–13). This study aimed to determine the potential
prebiotic activity of a puriﬁed 65% GOS content B-GOS,
compared with 52% GOS content B-GOS, used as positive
control in in vitro dose–response batch cultures.
Methods
Substrates
The two B-GOS products, supplied by Clasado BioSciences Ltd,
used in this study were produced from the activity of galacto-
syltransferases from B. biﬁdum NCIMB 41171 on lactose(14).
Both were used in syrup form. The B-GOS mixtures consisted
of (w/w) 52% GOS, 8% lactose, 22% glucose, 16·5% galactose
and 65% GOS, 10·1% lactose, 22% glucose, 1·8% galactose,
respectively.
Faecal inoculation
Experiments were carried out using fresh faecal samples from
three healthy donors (one female aged 26 years and two males
aged 25 and 31 years, respectively) who were free of any
metabolic and gastrointestinal diseases, were not taking pro-
biotic or prebiotic supplements and had not taken antibiotics
for 6 months before faecal sample donation. All donors then
provided written informed consent, and ﬁlled in a standard
questionnaire to collect information regarding health status,
drug use, clinical anamnesis and lifestyle factors. This study
was approved by The University of Reading Research Ethics
Committee (UREC 15/20). Faecal samples were placed in an
anaerobic jar (AnaeroJar™ 2.5L; Oxoid Ltd) including a gas-
generating kit (AnaeroGen™; Oxoid). Samples were diluted
1/10 w/w in anaerobic PBS (0·1mol/l phosphate buffer solu-
tion, pH 7·4) and homogenised (Stomacher 400; Seward) for
2min at 240 paddle beats/min. Samples were added to
anaerobic fermenters within 15min of voiding.
In vitro batch culture fermentation
This method was previously described by Rycroft et al.(15).
B-GOS were added at concentrations shown in Table 1 before
adding 5ml of faecal slurry (ﬁnal concentration of 1%). An extra
vessel with no added carbohydrate source was also included as
a negative control. The pH was maintained in the range of
6·7–6·9 via pH controllers (Fermac 260; Electrolab) and auto-
matically adjusted by adding 0·5mM-NaOH and HCl to the
vessels when required. The pH and temperature mimicked the
conditions of the distal region of the human large intestine.
Batch culture fermentations were run for 24 h, and the samples
(3·5ml from each vessel) were collected at 0, 4, 8 and 24 h for
analysis of bacterial populations and metabolite production.
Fermentation experiments were performed in triplicate.
Bacterial enumerations by ﬂuorescence in situ hybridisation
Differences in bacterial populations were assessed by ﬂuores-
cence in situ hybridisation (FISH) with oligonucleotide probes
designed to target speciﬁc diagnostic regions of 16S rRNA,
as previously described(16). The probes were commercially
synthesised and labelled at the 5′ end with the ﬂuorescent dye
Cy3 (Sigma-Aldrich) as reported in Table 2(17–22). Numbers of
speciﬁc and total bacteria were determined using the following
equation: DF×ACC× 6732·42× 50×DF sample, where DF is
the dilution factor (300/375= 0·8), ACC is the average cell count
of ﬁfteen ﬁelds of view and DF sample refers to the dilution of
sample used with a particular probe or stain. The ﬁgure 6732·42
refers to the area of the well divided by the area of the ﬁeld of
view and the factor 50 takes the cell count back to per millilitre
of sample.
SCFA analysis
Production of SCFA was determinate using GC as previously
described(23). Peaks were integrated using Agilent ChemStation
software (Agilent Technologies), and SCFA content was quan-
tiﬁed by single-point internal standard method. Peak identity
and internal response factors were determined using a 20-mM
calibration cocktail including acetic, propionic, iso-butyric,
butyric, iso-valeric, valeric, caproic and caprylic acids.
Table 1. Doses of the Bimuno® galacto-oligosaccharide (B-GOS) syrups
tested (equivalent to 0·1, 0·05 and 0·033g/l) in 100ml working volume
vessels during 24h of fermentation in pH- and volume-controlled batch
fermentation experiments
Vessel Treatment Syrup (g) DM GOS in 100ml
1 B-GOS (52% GOS content) 2·66 2 1
2 B-GOS (52% GOS content) 1·33 1 0·5
3 B-GOS (52% GOS content) 0·88 0·66 0·33
4 B-GOS (65% GOS content) 2·05 1·54 1
5 B-GOS (65% GOS content) 1·02 0·77 0·5
6 B-GOS (65% GOS content) 0·68 0·51 0·33
7 Negative control (only faeces)
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Metabolite analysis by 1H-NMR
Fermentation supernatants from all time points were defrosted,
vortexed and centrifuged at 599g for 5min. Supernatants were
ﬁltered using 0·22-µm low protein binding durapore poly-
vinylidene ﬂuoride membrane (Millex; EMD Millipore) and
400 μl was transferred into fresh eppendorf tubes. Filtered
samples were then combined with 200 μl of phosphate buffer
(0·2 M (pH 7·4) in D2O plus 0·001% trimethylsilyl propionate
(TSP)). The mixture was vortexed and centrifuged at 1136 g for
10min and then 550 μl was transferred into 5-mm NMR tubes for
analysis. All NMR spectra were acquired on Bruker Avance DRX
500MHz NMR Spectrometer (Bruker BioSpin) operating at
500MHz. They were acquired using a standard 1-dimensional
(1D) pulse sequence (recycle delay (RD) − 90° − t1 − 90° − tm−
90° − acquire free induction decay (FID)) with water suppres-
sion applied during RD of 2 s, a mixing time tm of 100ms and a
90 pulse set at 7·70 μs. For each spectrum, a total of 128 scans
were accumulated into 64 k data points with a spectral width of
12·001 parts per million. The FID were multiplied by an
exponential function corresponding to 0·3Hz line broadening.
All spectra were manually phased, baseline corrected and
calibrated to the chemical shift of TSP (δ 0·00). Spectra were
digitised using an in-house MATLAB (version R2014a; The
Mathworks Inc.) script. The spectral region containing the water
resonance was removed to minimise distortions in the baseline
arising from imperfect water saturation. Principal component
analysis (PCA) was performed with Pareto scaling using scripts
provided by Korrigan Sciences Ltd.
Statistical analysis
All statistical tests were performed using GraphPad Prism
(version 5.0; Graph-Pad Software). A two-way ANOVA test was
used to compare dose, substrates and time-dependent effects.
When there was no signiﬁcant effect, one-way ANOVA tests
and paired t tests, including post hoc tests appropriate for the
individual data sets (Bonferroni post-test with signiﬁcance set at
P< 0·05), were used for bacterial counts and organic acid
concentrations.
Results
SCFA analysis
Our results showed acetate as the dominant SCFA produced for
both substrates with signiﬁcant differences between 4 and 8 h of
fermentation using 65% B-GOS at 0·033 g/l (P< 0·01) (Table 3).
In particular, there was a clear dose–response effect during the
ﬁrst 4 h of fermentation. However, no signiﬁcant differences
were observed between the two substrates at the same dose.
The dose–response effect was also conﬁrmed by 1H-NMR data.
PCA revealed a clear trajectory over time, showing a clear
separation between 0 and 4 h with acetate as main component
inﬂuencing variation through time (Fig. 1). Signiﬁcant decreases
in propionate concentration throughout fermentation were
observed, mainly between 8 and 24 h of fermentation
(P< 0·01). None of the substrates generated major changes in
butyrate production (Table 3). Two-way ANOVA data analyses
did not show signiﬁcant differences on SCFA production
between the two substrates.
Changes in bacterial populations
A signiﬁcant increase in biﬁdobacteria was observed with 52%
B-GOS 0·5 and 0·33 g (equivalent to 0·05 and 0·033 g/l)
between time 0 and 24 h and with 65% B-GOS (P< 0·05)
at same doses at all time points tested (P< 0·05) (Table 4).
Table 2. Oligonucleotide probes used in the study for fluorescence in situ hybridisation analysis of bacterial populations
Probe name and sequence (5′–3′) Target species
Hybridisation-washing
temperature (°C) References
Bif164 CATCCGGCATTACCACCC Most Bifidobacterium spp. and Parascardovia denticolens 50–50 (20)
Bac303 CCAATGTGGGGGACCTT Most Bacteroides sensu stricto and Prevotella spp.;
all Parabacteroides; Barnesiella viscericola
and Odoribacter splanchnicus
46–48 (21)
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, Leuconostoc andWeissella spp.; Lactococcus
lactis; all Vagococcus, Enterococcus, Melissococcus,
Tetragenococcus, Catellicoccus, Pediococcus and
Paralactobacillus spp.
50–50 (22)
Chris150 TTATGCGGTATTAATCTYCCTTT Most members of Clostridium cluster I; all members
of Clostridium cluster II; Clostridium tyrobutyricum;
Adhaeribacter aquaticus and Flexibacter canadensis
(family Flexibacteriaceae); (Eubacterium) combesii
(family Propionibacteriaceae)
50–50 (23)
Erec 482 GCTTCTTAGTCARGTACCG Most members of Clostridium cluster XIVa; Syntrophococcus
sucromutans, (Bacteroides) galacturonicus and (Bacteroides)
xylanolyticus, Lachnospira pectinschiza and Clostridium
saccharolyticum
50–50 (23)
EUB338 I GCTGCCTCCCGTAGGAGT Total bacteria 46–48 (24)
EUB338 II GCAGCCACCCGTAGGTGT Total bacteria 46–48 (24)
EUB338 III GCTGCCACCCGTAGGTGT Total bacteria 46–48 (24)
Rrec584 TCAGACTTGCCGYACCGC Roseburia – Eubacterium rectale (a component of cluster XIVa) 50–50 (25)
Prop853 ATTGCGTTAACTCCGGCAC Clostridium cluster IX 50–50 (25)
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Table 3. SCFA production by GC in the pH-controlled and volume-controlled batch cultures at 0, 4, 8 and 24 h of fermentation†
(Mean of the data of three experiments and standard deviations)
Acetate (mM) Propionate (mM) Butyrate (mM) Branched (mM) Total (mM)
Substrates Time (h) Mean SD Mean SD Mean SD Mean SD Mean SD
0 26·77 22·13 6·50 7·25 4·63 5·11 15·60 17·26 53·49 51·53
52% B-GOS (1 g) 4 30·96 18·64 6·43 8·32 4·44 6·92 16·08 11·36 57·92 56·63
8 28·39 6·91 2·59 0·76 0·95 0·47 3·13 1·42 35·06 6·89
24 17·14 0·1 1·06 0·1 0·55 0·1 0·22 0·1 18·98 0·1
0 17·27 8·37 3·63 3·42 2·57 2·61 8·81 9·28 32·28 23·49
52% B-GOS (0·5 g) 4 28·33 19·27 4·67 6·09 2·29 3·41 7·71 11·36 43·01 40·13
8 31·25 15·30 2·11 1·65 0·80 0·51 1·37 0·98 35·52 18·34
24 20·3 0·1 0·91 0·1 0·39 0·1 0·23 0·1 21·84 0·1
0 11·41 8·94 2·26 1·92 1·63 1·52 5·74 5·89 21·04 16·22
52% B-GOS (0·33 g) 4 17·43 19·16 4·56 6·62 1·75 2·63 4·62 7·01 28·36 35·33
8 26·54 26·11 4·47 5·63 1·24 1·57 1·13 0·92 33·37 35·22
24 26·24 0·1 0·75 0·1 0·24 0·1 0·17 0·1 27·39 0·1
0 18·29 10·59 2·33 2·31 1·32 1·39 4·69 4·87 26·63 19·12
65% B-GOS (1 g) 4 38·42 22·17 4·65 4·45 1·42 1·91 4·47 5·65 48·97 34·11
8 43·37 28·55 6·81 5·19 1·21 0·99 1·47 1·15 52·82 33·81
24 6·78 0·1 0·73** 0·1 0·4 0·1 0·39 0·1 8·31 0·1
0 17·94 7·95 2·01 1·94 0·92 0·97 3·42 3·61 24·29 14·33
65% B-GOS (0·5 g) 4 30·61 20·92 3·97 3·69 1·27 1·59 3·19 3·95 39·03 30·10
8 24·43 11·06 3·32 2·47 0·72 0·56 1·18 0·81 29·65 13·96
24 21·51 0·1 0·61** 0·1 0·50 0·1 0·28 0·1 22·89 0·1
0 12·29 5·37 1·33 1·14 0·58 0·6 2·1 2·31 16·3 9·21
65% B-GOS (0·33 g) 4 24·68 15·65 3·39 3·19 0·84 1·03 2·14 2·65 31·05 22·49
8 27·18** 12·41 3·98 2·72 0·71 0·48 1·25 1·02 33·12 15·48
24 20·88 0·1 1·18* 0·1 0·97 0·1 0·77 0·1 23·79 0·1
0 5·28 5·69 0·71 0·51 0·36 0·32 1·15 1·25 7·5 5·34
Negative control 4 8·68 5·25 1·68 0·97 0·61 0·47 1·3 1·66 12·31 8·28
8 18·82 8·74 2·71 1·47 0·67 0·12 0·97 0·84 23·17 10·64
24 18·43 0·1 2·37 0·1 1·47 0·1 0·49 0·1 22·76 0·1
B-GOS, Bimuno® galacto-oligosaccharide.
* Significantly different from 0h with P<0·05.
** Significantly different from 0h with P<0·01 (one-way ANOVA).
† 52% B-GOS and 65% B-GOS at doses 1, 0·5 and 0·33g (equivalent to 0·1, 0·05 and 0·033g/l).
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Fig. 1. 1H-NMR data analysis. (a–c) Principal component (PC) analysis (PCA) score plot B-GOS 65% – T4 and PCA score plot B-GOS 52% – T4, respectively, show
a clear separation during the first 4 h of fermentation due to dose–response effect. (b–d) PCA score plot B-GOS 65% – T8 and PCA score plot B-GOS 52% – T8,
respectively, show how the dose effect is lost after 4 h of fermentation. (e) The colour plot illustrates the main compound, acetate, influencing the separation. The 65%
B-GOS and 52% B-GOS were tested at 1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 0·033 g/l. a, b: , 65% B-GOS 0·33 g; , 65% B-GOS 0·5 g; , 65% B-GOS 1g;
c, d: , 52% B-GOS 0·33g; , 52% B-GOS 0·5g; , 52% B-GOS 1g.
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Lactobacilli signiﬁcantly increased after addition of 52% B-GOS
and 65% B-GOS 1 and 0·33 g (equivalent to 0·1 and 0·033 g/l)
(P< 0·01) and 52% B-GOS 0·5 g (equivalent to 0·05 g/l)
(P< 0·05) between 8 and 24 h. An overall decrease in the
Bacteroides–Provotella group with 52% B-GOS at doses of 1
and 0·33 g (equivalent to 0·1 and 0·033 g/l) was observed
between 0 and 24 h (P< 0·05). With 65% B-GOS at 1 and 0·5 g
(equivalent to 0·1 and 0·05 g/l), there was a signiﬁcant decrease
between 4 and 24 and 0 and 4 h, respectively (P< 0·05). Two-
way ANOVA data analyses did not show signiﬁcant differences
in microbiota composition between the two substrates.
Discussion
The present study was carried out in order to evaluate the in vitro
fermentation properties of B-GOS (65% GOS content) in pH- and
volume-controlled batch culture fermentation. The fermentability
and the selectivity of GOS have been previously evaluated in vitro
by several comparative studies. Rycroft et al.(15) compared
the efﬁcacy of different prebiotics including FOS and GOS in
24-h batch culture experiments, and the results show how
GOS induced the largest signiﬁcant increases in biﬁdobacteria,
lactobacilli and total bacterial numbers during fermentation(15).
In our study, the administration of B-GOS showed the same
trend, especially considering the biﬁdobacteria and lactobacilli
population. There was also a signiﬁcant decrease in Bacteroidetes
numbers, except for 52% B-GOS at 0·05g/l and 65% B-GOS at
0·033g/l. The 65% B-GOS also has a strong inﬂuence in the
production of SCFA, compared with B-GOS that is commercially
available (52% GOS content). Our results showed a double
increase in acetate production at all doses using 65% B-GOS, but
were not signiﬁcant, except for 65% B-GOS at 0·033g/l, probably
due to the high standard deviation.
The fermentation of all different doses induced the produc-
tion of acetate, which correlated with an increase in
Biﬁdobacterium populations(24). Palframan et al.(25) in a study
comparing the effect of the pH and dose on batch culture
Table 4. Bacterial groups detected by fluorescence in situ hybridisation in the pH-controlled and volume-controlled batch cultures at 0, 4, 8 and 24h of
fermentation*
(Mean of the data of three experiments and standard deviations; n 3)
Bacterial population (log10 cells/ml)
52% B-GOS
1g
52% B-GOS
0·5 g
52% B-GOS
0·33g
65% B-GOS
1g
65% B-GOS
0·5 g
65% B-GOS
0·33 g NC
Probes Time point (h) Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Eub338 I-II-III 0 9·24 0·09 9·13 0·11 9·22 0·11 9·24 0·11 9·27 0·12 9·23 0·1 9·19 0·08
4 9·11 0·17 9·15 0·18 9·14 0·44 9·39 0·14 8·9 0·14 9·35 0·07 9·04 0·31
8 9·16 0·13 9·49 0·23 9·05 0·41 9·52 0·1 8·92 0·1 9·46 0·04 9·2 0·59
24 9·14 0·01 9·33 0·03 9·1 0·05 8·94a,c 0·07 9·21 0·01 9·56a 0·04 8·95a 0·02
Lab158 0 7·63 0·09 7·48 0·11 7·55 0·05 7·52 0·07 7·54 0·15 7·47 0·06 7·48 0·06
4 7·57 0·05 7·64 0·16 7·77 0·27 7·78 0·14 7·73 0·12 7·31 0·29 7·54 0·2
8 7·74 0·1 8·05 0·11 7·6 0·36 7·98 0·27 8·21 0·56 7·66 0·12 7·55 0·4
24 8·39a,b,c 0·02 7·70c 0·01 7·94a 0·07 7·94a 0·09 7·68 0·06 7·85a 0·05 7·29a 0·08
Bif164 0 8·61 0·28 8·7 0·17 8·58 0·26 8·45 0·35 8·63 0·21 8·47 0·3 8·68 0·21
4 8·73 0·33 9·1 0·22 8·79 0·67 8·86b 0·2 8·75 0·19 8·47 0·4 8·45 0·31
8 8·93 0·29 8·87 0·61 8·95 0·63 9·12 0·21 9·25a,b 0·04 9·31a,b 0·1 8·53 0·13
24 9·2 0·06 9·31a 0·03 9·19a 0·08 9·12 0·21 9·2a,b 0·07 9·24a 0·04 8·25 0·07
Bac303 0 8·26 0·16 8·23 0·35 8·27 0·33 8·33 0·25 8·33 0·3 8·2 0·19 8·26 0·29
4 8·07 0·55 8·41 0·53 8·09 0·86 8·49 0·15 7·94a 0·26 8·39 0·12 7·75 0·83
8 7·33 0·64 7·83 0·82 8·11 0·66 8·31 0·46 7·88 0·32 8·63 0·19 6·71a 0·37
24 7·78a 0·05 8·39 0·15 7·06a 0·2 7·94b 0·03 8·41 0·06 8·29 0·04 8·39a,c 0·2
Erec482 0 8·35 0·16 8·34 0·13 8·42 0·03 8·34 0·06 8·38 0·09 8·3 0·04 8·32 0·05
4 8·29 0·12 8·39 0·15 8·17 0·31 8·4 0·21 8·36 0·2 8·24 0·34 8·08 0·43
8 7·85 1·21 7·92 1·42 7·88 1·22 7·91 1·36 8·45 0·08 8·38 0·38 7·98 0·76
24 8·85a,b 0·37 8·65a 0·06 7·94a 0·04 8·58a 0·01 8·59a 0·01 8·56a 0·04 8·06a 0·05
Rrec584 0 8·34 0·25 8·24 0·08 8·06 0·54 8·15 0·3 8·17 0·17 8·28 0·09 8·34 0·04
4 7·54 1·04 8·13 0·3 7·85 0·59 8·2 0·41 7·29 0·86 7·77 0·62 7·78 0·69
8 7·06 0·87 7·47 0·74 7·37a 0·78 7·71 0·98 7·21 0·78 7·6 0·56 7·66a 0·21
24 7·2 0·02 7·14a,b 0·05 6·92 0·01 7·78 0·14 7·23a 0·06 8·51a 0·03 7·54a 0·2
Chis150 0 5·83 0·2 5·73 1·1 5·83 0·2 5·73 1·1 5·93 0·3 5·73 1·1 5·73 1·1
4 5·86 0·04 6·34 0·5 5·79 0·1 6·56 0·6 6·11 0·2 6·2 0·3 5·9 0·1
8 6·03 0·1 6·74 1 6·53 1 6·80 1·1 6·92 1·3 7·24 0·8 5·87 0·2
24 5·73 0·02 5·73 0·05 7·45 0·01 5·73 0·2 6·43 0·03 5·73 0·01 5·73 0·01
Prop853 0 7·98 0·18 7·97 0·27 8·05 0·22 8·18 0·26 8·16 0·22 8·08 0·22 8·04 0·06
4 8·04 0·28 7·97 0·02 7·81 0·47 8·02 0·09 8·02 0·05 8·11 0·09 7·99 0·19
8 7·84 0·37 7·74 0·48 7·83 0·37 7·85a 0·68 7·67a 1·03 8·16a 0·3 7·76a 0·08
24 8·19b,c 0·01 7·99 0·01 7·95a,b 0·04 6·53b 0·02 6·15b 0·06 8·72b,c 0·01 8·1c 0·07
B-GOS, Bimuno® galacto-oligosaccharide.
a Significantly different from 0h with P<0·05; b significantly different from 4h with P< 0·05; c significantly different from 8h with P<0·05; italicised superscript letters were
significantly different with P< 0·01; bold superscript letters were significantly different with P< 0·001 (t test).
* The 65% B-GOS and 52% B-GOS were tested at 1, 0·5 and 0·33g (equivalent to 0·1, 0·05 and 0·033g/l).
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fermentation of ﬁve commercial prebiotics have shown similar
results. FISH analysis showed how the highest bacterial num-
bers were obtained with GOS at pH 6 and 1% (w/v)(25). The
global effect on the bacterial population of 52% B-GOS has
been tested in a previous fermentation study where the com-
mercial B-GOS mixture was compared with different puriﬁed
GOS. Using the Selectivity Index (SI) as a value for the growth
of beneﬁcial bacteria, Rodriguez-Colinas et al.(26) have shown
that 52% B-GOS had the highest SI, and consequently a strong
degree of selectivity for Biﬁdobacterium population.
Our results highlighted that 65% GOS had an effective pre-
biotic activity, in terms of increasing the number of biﬁdo-
bacteria and metabolite production. This was especially seen
for acetate, probably due to the lower content of mono-
saccharides and disaccharides in the mixture that might have
affected in vitro fermentation experiments overall. However,
a previous study of Costabile et al.(27) has demonstrated that the
carbohydrates that remained after the in vitro pre-digestion
process did not have any selective properties to invoke a biﬁ-
dogenic effect, which perhaps would not persist in vivo(28).
In our study, major changes in other bacterial populations
were seen, which might be due to the presence of these sugars.
Different concentrations of SCFA have been identiﬁed at time 0, but
it may be explained by the high inter-individual variability among
each individual. Signiﬁcant differences were observed between
the time points in all analyses but not between the two substrates.
The effects of B-GOS 52% as a potential modulator of the gut
microﬂora and the immune system have been extensively
investigated in several human intervention studies. The 65%
B-GOS has shown a signiﬁcant modulation of health-promoting
beneﬁcial bacteria, and our ﬁndings proved that reducing
impurities in the prebiotic mixture might improve the selectivity
of prebiotics in in vitro experiments. However, the comparison
between the effect of 65% B-GOS and 52% B-GOS has shown
similar biﬁdogenic effects (data not published). The applic-
ability of such changes remains to be investigated in in vivo
human intervention studies.
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